Fukushima Ryan sold $1.9M of TEM (indirect holdings)

Fukushima Ryan (CEO, Data) sold 33,284 indirectly-held shares of Tempus AI, Inc. (TEM) at an average of $57.39 ($56.80–$59.47, $1.91M total) across 4 trades on 2026-07-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Fukushima Ryan
Published Jul 10, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 10, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TEM
Neutral
medium confidence
Mentioned
$TEM
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEMNeutralLow
01

Why it matters

The newest actionable element is the disclosed sale size, execution window (July 8), and the fact it was conducted under a pre-arranged 10b5-1 plan.

02

Market read

This provides a fresh datapoint on insider liquidity and potential sentiment, but the 10b5-1 structure limits fundamental inference.

03

What to watch

Traders may want to compare this sale to prior insider activity cadence and whether other executives filed similar 10b5-1 sales around the same dates.

Relevance 5/10Novelty 5/10Timing: Filed July 10, covering sales executed July 8.

Background

The article is an SEC Form 4 insider transaction disclosure for Tempus AI, Inc., reported by CEO Data Fukushima Ryan.

Company-level read

Ticker impact

$TEMNeutralMedium confidence
Context

Tempus AI CEO Fukushima Ryan sold $1.91M of TEM shares via a Rule 10b5-1 plan, with 33,284 shares sold at $56.80–$59.47.

Expected impact

Likely limited, short-lived impact unless follow-on selling or other negative catalysts emerge.

Evidence & confidence

The filing is a primary Form 4 disclosure and the transaction size is meaningful, but the article specifies it was pre-arranged under Rule 10b5-1, reducing interpretive weight.

Market effects

Minimal sector read-through; this is company-specific insider transaction disclosure rather than a sector catalyst.

No clear regional spillover implied by the filing details.

No global macro or cross-border transaction effects indicated.

Counterpoint

Because the sale is 10b5-1 pre-arranged, it may reflect routine liquidity needs rather than bearish fundamentals, so the market reaction could be overstated.

Key entities

  • Tempus AI, Inc.

    Subject of the Form 4 insider sale disclosure (TEM).

  • Fukushima Ryan

    CEO, Data, who reported an indirect open-market sale under a Rule 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Tempus CEO Eric Lefkofsky: A Blood Draw Can Catch Returning Cancer 6 to 12 Months Before a Scan

Tempus CEO Eric Lefkofsky reported a record quarter with 23% revenue growth, driven by 32% growth in cancer testing and 33% in data & AI applications. The company signed three $100M+ deals, including with Merck and Bristol Myers Squibb. Tempus claims its blood tests can detect cancer recurrence 6-12 months earlier than scans, leveraging its 600-petabyte data trove and 8,000 hospital integrations. The company is acquiring Personalis to expand into recurrence detection.

$TEMMedAI 8/10

BTIG raises Tempus AI stock price target to $100 on data deals

BTIG raised its price target for Tempus AI (NASDAQ:TEM) to $100, citing strong quarterly results, raised guidance, and significant data deals, including a $200M agreement with Bristol Myers Squibb. The company reported 50% revenue growth and positive adjusted EBITDA. Other analysts also raised price targets, noting strong performance in data and diagnostics segments.

$TEMLow

Jefferies upgrades Tempus AI stock rating to hold, raises price target to $70

Jefferies upgraded Tempus AI (TEM) from Underperform to Hold, raising its price target to $70. The stock, currently at $78.48, has gained 43% in six months. The firm cited strong revenue growth, strategic collaborations, and FDA approval plans. Tempus reported Q3 2026 earnings of $0.07 per share, beating estimates, with revenue up 23% to $411.5 million. Needham raised its price target to $89, citing data business growth.

$TEMMed

Tempus AI Inc (TEM) Q3 2026 Earnings Call Highlights: Revenue Jumps 23%

Tempus AI Inc (TEM) reported Q3 2026 revenue of $411M, up 23%. CEO Lefkofsky expects sustainable 25%+ growth, with oncology and data segments driving performance. The company anticipates mid-2027 breakeven for Personalis' MRD test and predicts strong market share in MRD. Tempus also highlighted long-term data business commitments and AI-driven customer stickiness.